• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology >Subcutaneous trastuzumab (Herceptin) injection shows promise.
【24h】

Subcutaneous trastuzumab (Herceptin) injection shows promise.

机译：皮下曲妥珠单抗（赫赛汀）注射显示出前景。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A subcutaneous formulation of trastuzumab (Herceptin) may soon be available. The results of the phase III, open-label, international, neoadjuvant HannaH trial, published in The Lancet Oncology,[1] show early, promising data that the subcutaneous formulation of trastuzumab is as efficacious and safe as the intravenous (IV) version.If disease-free survival and overall survival rates equal those of trastuzumab given intravenously, patients could find themselves administering the subcutaneous version of the drugThe study found the pathologic complete response of the subcutaneous dose to be comparable to the IV formulation. Of the patients who received the subcutaneous formulation, 45.4% achieved a pathologic complete response compared with 40.7% of patients who received IV-administered trastuzumab. The median time to response was 6 weeks in both study arms.
机译：曲妥珠单抗（赫赛汀）的皮下制剂可能很快就会上市。发表于《柳叶刀》杂志[1]的III期开放标签国际新辅助HannaH试验的结果表明，早期有希望的数据表明曲妥珠单抗的皮下制剂与静脉注射（IV）版本一样有效和安全。如果无病生存率和总生存率等于静脉注射曲妥珠单抗，则患者可以自行服用皮下注射药物。研究发现，皮下注射剂量的病理完全反应与静脉注射制剂相当。在接受皮下制剂治疗的患者中，有45.4％达到了病理完全缓解，而接受静脉注射曲妥珠单抗的患者为40.7％。两个研究组的中位反应时间为6周。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号